Lantheus Holdings Stock News

Equities analysts expect that Lantheus Holdings, Inc. (NASDAQ:LNTH) will post $112.85 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Lantheus earnings. The highest sales estimate is $113.50 million and the lowest is $112.20 million. Lantheus reported sales of $94.15 million during the same quarter last year, which []

NORTH BILLERICA, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today poster presentations featuring PYLARIFY ® (piflufolastat F 18) data from the Company’s Phase 3 CONDOR study at the upcoming Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which will be held from November 28 - December 2, 2021 in Chicago, IL and the 22 nd Annual Meeting of the Society for Urologic Oncology (SUO), which will be held from December 1-3, 2021 in Orlando, FL.

NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the 4th Annual Evercore ISI HealthCONx Conference at 1:00 p.m. ET on Tuesday, November 30.

NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagno

Charles Schwab Investment Management Inc. grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 467,014 shares of the medical equipment providers stock after buying an additional 12,012 shares during the quarter. Charles Schwab []

Zacks Investment Research cut shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a research report released on Saturday morning, Zacks.com reports. According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves […]

Lantheus (NASDAQ:LNTH) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Saturday, Zacks.com reports. According to Zacks, Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, []

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q3 2021 Results - Earnings Call Transcript

NORTH BILLERICA, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagno

NORTH BILLERICA, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on

NORTH BILLERICA, Mass. and HAYWARD, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) and RefleXion Medical, Inc., today announced a development and commerci

Highlights Piflufolastat F 18's Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer

NORTH BILLERICA, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagn

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q2 2021 Results - Earnings Call Transcript